Physician profile
Roopa Sathyaprakash
NPI 1588706519
$15,076.67
in general payments reported to CMS, 2019-2025
61 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $1,893 · 2021: $2,240 · 2022: $1,973 · 2023: $1,901 · 2024: $2,509 · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,900 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,900.23 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,241.71 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $1,507.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,275.31 | 2019-2023 | Farxiga |
| Abbott Laboratories | $897.65 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $825.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $788.07 | 2019-2025 | Jardiance |
| Amgen INC. | $639.81 | 2019-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $518.10 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $469.41 | 2022-2025 | |
| Dexcom, INC. | $384.87 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $362.02 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $340.10 | 2019-2022 | |
| Antares Pharma, INC. | $333.88 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Ibsa Pharma INC. | $312.15 | 2019-2025 | Licart, Tirosint, Flector |
| Amneal Pharmaceuticals LLC | $289.13 | 2019-2025 | Unithroid |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $275.70 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $263.09 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $226.70 | 2021-2025 | Strensiq |
| Medtronic, INC. | $210.09 | 2022-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $162.64 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $161.52 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $158.38 | 2022-2024 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $143.97 | 2023-2025 | Isturisa, Signifor Lar |
| Corcept Therapeutics | $138.25 | 2023-2025 | Korlym |
| Neurocrine Biosciences, INC. | $137.42 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $126.29 | 2019 | |
| Tandem Diabetes Care, INC. | $117.49 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $107.01 | 2019-2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $102.48 | 2019-2022 | |
| Becton, Dickinson and Company | $102.20 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $98.35 | 2023-2025 | NP Thyroid 60 |
| Sequel Med Tech, LLC | $93.60 | 2025 | Twiist |
| Currax Pharmaceuticals LLC | $78.76 | 2020-2024 | Contrave |
| Ultragenyx Pharmaceutical INC. | $72.99 | 2021 | |
| Astellas Pharma US INC | $71.88 | 2024-2025 | Veozah |
| Horizon Therapeutics Plc | $69.91 | 2023 | Tepezza |
| Vivus LLC | $69.62 | 2020-2024 | Qsymia |
| Nevro Corp. | $68.81 | 2023-2024 | Senza |
| Madrigal Pharmaceuticals | $68.33 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $61.11 | 2019-2020 | |
| Vistapharm, INC. | $55.04 | 2021 | |
| Abbvie INC. | $53.33 | 2019-2020 | |
| Pfizer INC. | $51.67 | 2022-2023 | |
| Kyowa Kirin, INC. | $48.47 | 2024-2025 | Crysvita |
| Shire North American Group INC | $47.84 | 2019 | |
| Halozyme INC | $42.78 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.94 | 2020 | |
| Tolmar, INC. | $37.19 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $37.17 | 2023-2025 | Baqsimi |
| Clarus Therapeutics INC. | $37.11 | 2021 | |
| Avvisto Therapeutics, LLC | $30.40 | 2024-2025 | Cycloset |
| Bolton Medical INC | $29.76 | 2025 | Treo Abdominal Stent-Graft System |
| Zealand Pharma US, INC. | $29.33 | 2021 | |
| Companion Medical, INC. | $29.16 | 2020 | |
| Acerus Pharmaceuticals Corporation | $26.02 | 2020 | |
| Glaxosmithkline, LLC. | $20.72 | 2025 | Shingrix, Arexvy |
| Ascensia Diabetes Care US INC. | $19.53 | 2025 | |
| Alvogen INC | $18.48 | 2022 | |
| Intuity Medical INC | $18.28 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amryt Pharma Holdings Ltd | $17.10 | 2023 | Mycapssa |
| Lifescan, INC. | $15.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Sathyaprakash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.